Global Infectious Diseases

Infectious Diseases Comprehensive Study by Type (Reagents and Kits, Instrument, Software), Infectious Disease Type (Viral Infections, Bacterial Infections, Fungal Infections, Parasitic Infections, Others), Technology (Immunodiagnostics, Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), DNA Sequencing and Next-Generation Sequencing (NGS), DNA Microarray, Others), End User (Hospitals and Clinics, Laboratories, Academic and Research Institutes, Others) Players and Region - Global Market Outlook to 2030

Infectious Diseases Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Infectious diseases are illnesses triggered by microorganisms like bacteria, viruses, fungi, or parasites. The human body host various organisms, usually harmless or beneficial. However, specific conditions can turn some of these organisms into harmful agents that cause diseases. The global infectious diseases market is influenced by several key factors. Growing awareness about infectious diseases and advancements in diagnostic technologies are driving market expansion. Additionally, the increasing incidence of emerging infectious diseases, along with the rise in healthcare expenditure globally, fuels the market growth. However, stringent regulatory policies and high costs associated with research and development pose significant challenges to market players. On the other hand, technological innovations, especially in genomics and immunotherapies, present promising opportunities for market growth. Moreover, the ongoing efforts to control and prevent infectious diseases, coupled with investments in healthcare infrastructure in developing economies, further contribute to shaping the market's landscape.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledQuagen Pharma (United States), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Bio-Rad Laboratories Inc. (United States), Danaher Corporation (United States), DiaSorin S.p.A. (Italy), BD (United States), Abbott (United States), Siemens (Germany), Thermo Fisher Scientific Inc. (United States), Johnson and Johnson Private Limited (United States), Cepheid (United States), OraSure Technologies, Inc. (United States), Meridian Bioscience Inc. (United States), Quidel Corporation (United States) and Grifols (Spain)


This growth is primarily driven by Growing awareness about infectious diseases and Advancements in diagnostic technologies.

Globally, a noticeable market trend is evident Major Players, such as Quagen Pharma (United States), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Bio-Rad Laboratories Inc. (United States), Danaher Corporation (United States), DiaSorin S.p.A. (Italy), BD (United States), Abbott (United States), Siemens (Germany), Thermo Fisher Scientific Inc. (United States), Johnson and Johnson Private Limited (United States), Cepheid (United States), OraSure Technologies, Inc. (United States), Meridian Bioscience Inc. (United States), Quidel Corporation (United States) and Grifols (Spain), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Market Growth Drivers:
Growing awareness about infectious diseases and Advancements in diagnostic technologies

Challenges:
Stringent regulatory policies

Restraints:
High cost associated with R&D

Opportunities:
Rise in the healthcare infrastructure and Growing R&D activities

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Infectious Diseases Market
- Analysis about New Entrants in Infectious Diseases Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Infectious Diseases Study Sheds Light on
— The Infectious Diseases Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Infectious Diseases industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Infectious Diseases industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Reagents and Kits
  • Instrument
  • Software
By Infectious Disease Type
  • Viral Infections
  • Bacterial Infections
  • Fungal Infections
  • Parasitic Infections
  • Others

By Technology
  • Immunodiagnostics
  • Polymerase Chain Reaction (PCR)
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • DNA Sequencing and Next-Generation Sequencing (NGS)
  • DNA Microarray
  • Others

By End User
  • Hospitals and Clinics
  • Laboratories
  • Academic and Research Institutes
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing awareness about infectious diseases
      • 3.2.2. Advancements in diagnostic technologies
    • 3.3. Market Challenges
      • 3.3.1. Stringent regulatory policies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Infectious Diseases, by Type, Infectious Disease Type, Technology, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Infectious Diseases (Value)
      • 5.2.1. Global Infectious Diseases by: Type (Value)
        • 5.2.1.1. Reagents and Kits
        • 5.2.1.2. Instrument
        • 5.2.1.3. Software
      • 5.2.2. Global Infectious Diseases by: Infectious Disease Type (Value)
        • 5.2.2.1. Viral Infections
        • 5.2.2.2. Bacterial Infections
        • 5.2.2.3. Fungal Infections
        • 5.2.2.4. Parasitic Infections
        • 5.2.2.5. Others
      • 5.2.3. Global Infectious Diseases by: Technology (Value)
        • 5.2.3.1. Immunodiagnostics
        • 5.2.3.2. Polymerase Chain Reaction (PCR)
        • 5.2.3.3. Isothermal Nucleic Acid Amplification Technology (INAAT)
        • 5.2.3.4. DNA Sequencing and Next-Generation Sequencing (NGS)
        • 5.2.3.5. DNA Microarray
        • 5.2.3.6. Others
      • 5.2.4. Global Infectious Diseases by: End User (Value)
        • 5.2.4.1. Hospitals and Clinics
        • 5.2.4.2. Laboratories
        • 5.2.4.3. Academic and Research Institutes
        • 5.2.4.4. Others
      • 5.2.5. Global Infectious Diseases Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Infectious Diseases: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Quagen Pharma (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BioMérieux (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bio-Rad Laboratories Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Danaher Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. DiaSorin S.p.A. (Italy)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. BD (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Abbott (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Siemens (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Thermo Fisher Scientific Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Johnson and Johnson Private Limited (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Cepheid (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. OraSure Technologies, Inc. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Meridian Bioscience Inc. (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Quidel Corporation (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Grifols (Spain)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
  • 7. Global Infectious Diseases Sale, by Type, Infectious Disease Type, Technology, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Infectious Diseases (Value)
      • 7.2.1. Global Infectious Diseases by: Type (Value)
        • 7.2.1.1. Reagents and Kits
        • 7.2.1.2. Instrument
        • 7.2.1.3. Software
      • 7.2.2. Global Infectious Diseases by: Infectious Disease Type (Value)
        • 7.2.2.1. Viral Infections
        • 7.2.2.2. Bacterial Infections
        • 7.2.2.3. Fungal Infections
        • 7.2.2.4. Parasitic Infections
        • 7.2.2.5. Others
      • 7.2.3. Global Infectious Diseases by: Technology (Value)
        • 7.2.3.1. Immunodiagnostics
        • 7.2.3.2. Polymerase Chain Reaction (PCR)
        • 7.2.3.3. Isothermal Nucleic Acid Amplification Technology (INAAT)
        • 7.2.3.4. DNA Sequencing and Next-Generation Sequencing (NGS)
        • 7.2.3.5. DNA Microarray
        • 7.2.3.6. Others
      • 7.2.4. Global Infectious Diseases by: End User (Value)
        • 7.2.4.1. Hospitals and Clinics
        • 7.2.4.2. Laboratories
        • 7.2.4.3. Academic and Research Institutes
        • 7.2.4.4. Others
      • 7.2.5. Global Infectious Diseases Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Infectious Diseases: by Type(USD Million)
  • Table 2. Infectious Diseases Reagents and Kits , by Region USD Million (2018-2023)
  • Table 3. Infectious Diseases Instrument , by Region USD Million (2018-2023)
  • Table 4. Infectious Diseases Software , by Region USD Million (2018-2023)
  • Table 5. Infectious Diseases: by Infectious Disease Type(USD Million)
  • Table 6. Infectious Diseases Viral Infections , by Region USD Million (2018-2023)
  • Table 7. Infectious Diseases Bacterial Infections , by Region USD Million (2018-2023)
  • Table 8. Infectious Diseases Fungal Infections , by Region USD Million (2018-2023)
  • Table 9. Infectious Diseases Parasitic Infections , by Region USD Million (2018-2023)
  • Table 10. Infectious Diseases Others , by Region USD Million (2018-2023)
  • Table 11. Infectious Diseases: by Technology(USD Million)
  • Table 12. Infectious Diseases Immunodiagnostics , by Region USD Million (2018-2023)
  • Table 13. Infectious Diseases Polymerase Chain Reaction (PCR) , by Region USD Million (2018-2023)
  • Table 14. Infectious Diseases Isothermal Nucleic Acid Amplification Technology (INAAT) , by Region USD Million (2018-2023)
  • Table 15. Infectious Diseases DNA Sequencing and Next-Generation Sequencing (NGS) , by Region USD Million (2018-2023)
  • Table 16. Infectious Diseases DNA Microarray , by Region USD Million (2018-2023)
  • Table 17. Infectious Diseases Others , by Region USD Million (2018-2023)
  • Table 18. Infectious Diseases: by End User(USD Million)
  • Table 19. Infectious Diseases Hospitals and Clinics , by Region USD Million (2018-2023)
  • Table 20. Infectious Diseases Laboratories , by Region USD Million (2018-2023)
  • Table 21. Infectious Diseases Academic and Research Institutes , by Region USD Million (2018-2023)
  • Table 22. Infectious Diseases Others , by Region USD Million (2018-2023)
  • Table 23. South America Infectious Diseases, by Country USD Million (2018-2023)
  • Table 24. South America Infectious Diseases, by Type USD Million (2018-2023)
  • Table 25. South America Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 26. South America Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 27. South America Infectious Diseases, by End User USD Million (2018-2023)
  • Table 28. Brazil Infectious Diseases, by Type USD Million (2018-2023)
  • Table 29. Brazil Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 30. Brazil Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 31. Brazil Infectious Diseases, by End User USD Million (2018-2023)
  • Table 32. Argentina Infectious Diseases, by Type USD Million (2018-2023)
  • Table 33. Argentina Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 34. Argentina Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 35. Argentina Infectious Diseases, by End User USD Million (2018-2023)
  • Table 36. Rest of South America Infectious Diseases, by Type USD Million (2018-2023)
  • Table 37. Rest of South America Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 38. Rest of South America Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 39. Rest of South America Infectious Diseases, by End User USD Million (2018-2023)
  • Table 40. Asia Pacific Infectious Diseases, by Country USD Million (2018-2023)
  • Table 41. Asia Pacific Infectious Diseases, by Type USD Million (2018-2023)
  • Table 42. Asia Pacific Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 43. Asia Pacific Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 44. Asia Pacific Infectious Diseases, by End User USD Million (2018-2023)
  • Table 45. China Infectious Diseases, by Type USD Million (2018-2023)
  • Table 46. China Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 47. China Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 48. China Infectious Diseases, by End User USD Million (2018-2023)
  • Table 49. Japan Infectious Diseases, by Type USD Million (2018-2023)
  • Table 50. Japan Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 51. Japan Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 52. Japan Infectious Diseases, by End User USD Million (2018-2023)
  • Table 53. India Infectious Diseases, by Type USD Million (2018-2023)
  • Table 54. India Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 55. India Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 56. India Infectious Diseases, by End User USD Million (2018-2023)
  • Table 57. South Korea Infectious Diseases, by Type USD Million (2018-2023)
  • Table 58. South Korea Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 59. South Korea Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 60. South Korea Infectious Diseases, by End User USD Million (2018-2023)
  • Table 61. Taiwan Infectious Diseases, by Type USD Million (2018-2023)
  • Table 62. Taiwan Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 63. Taiwan Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 64. Taiwan Infectious Diseases, by End User USD Million (2018-2023)
  • Table 65. Australia Infectious Diseases, by Type USD Million (2018-2023)
  • Table 66. Australia Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 67. Australia Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 68. Australia Infectious Diseases, by End User USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Infectious Diseases, by Type USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 72. Rest of Asia-Pacific Infectious Diseases, by End User USD Million (2018-2023)
  • Table 73. Europe Infectious Diseases, by Country USD Million (2018-2023)
  • Table 74. Europe Infectious Diseases, by Type USD Million (2018-2023)
  • Table 75. Europe Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 76. Europe Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 77. Europe Infectious Diseases, by End User USD Million (2018-2023)
  • Table 78. Germany Infectious Diseases, by Type USD Million (2018-2023)
  • Table 79. Germany Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 80. Germany Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 81. Germany Infectious Diseases, by End User USD Million (2018-2023)
  • Table 82. France Infectious Diseases, by Type USD Million (2018-2023)
  • Table 83. France Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 84. France Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 85. France Infectious Diseases, by End User USD Million (2018-2023)
  • Table 86. Italy Infectious Diseases, by Type USD Million (2018-2023)
  • Table 87. Italy Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 88. Italy Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 89. Italy Infectious Diseases, by End User USD Million (2018-2023)
  • Table 90. United Kingdom Infectious Diseases, by Type USD Million (2018-2023)
  • Table 91. United Kingdom Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 92. United Kingdom Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 93. United Kingdom Infectious Diseases, by End User USD Million (2018-2023)
  • Table 94. Netherlands Infectious Diseases, by Type USD Million (2018-2023)
  • Table 95. Netherlands Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 96. Netherlands Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 97. Netherlands Infectious Diseases, by End User USD Million (2018-2023)
  • Table 98. Rest of Europe Infectious Diseases, by Type USD Million (2018-2023)
  • Table 99. Rest of Europe Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 100. Rest of Europe Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 101. Rest of Europe Infectious Diseases, by End User USD Million (2018-2023)
  • Table 102. MEA Infectious Diseases, by Country USD Million (2018-2023)
  • Table 103. MEA Infectious Diseases, by Type USD Million (2018-2023)
  • Table 104. MEA Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 105. MEA Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 106. MEA Infectious Diseases, by End User USD Million (2018-2023)
  • Table 107. Middle East Infectious Diseases, by Type USD Million (2018-2023)
  • Table 108. Middle East Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 109. Middle East Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 110. Middle East Infectious Diseases, by End User USD Million (2018-2023)
  • Table 111. Africa Infectious Diseases, by Type USD Million (2018-2023)
  • Table 112. Africa Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 113. Africa Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 114. Africa Infectious Diseases, by End User USD Million (2018-2023)
  • Table 115. North America Infectious Diseases, by Country USD Million (2018-2023)
  • Table 116. North America Infectious Diseases, by Type USD Million (2018-2023)
  • Table 117. North America Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 118. North America Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 119. North America Infectious Diseases, by End User USD Million (2018-2023)
  • Table 120. United States Infectious Diseases, by Type USD Million (2018-2023)
  • Table 121. United States Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 122. United States Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 123. United States Infectious Diseases, by End User USD Million (2018-2023)
  • Table 124. Canada Infectious Diseases, by Type USD Million (2018-2023)
  • Table 125. Canada Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 126. Canada Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 127. Canada Infectious Diseases, by End User USD Million (2018-2023)
  • Table 128. Mexico Infectious Diseases, by Type USD Million (2018-2023)
  • Table 129. Mexico Infectious Diseases, by Infectious Disease Type USD Million (2018-2023)
  • Table 130. Mexico Infectious Diseases, by Technology USD Million (2018-2023)
  • Table 131. Mexico Infectious Diseases, by End User USD Million (2018-2023)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Company Basic Information, Sales Area and Its Competitors
  • Table 147. Company Basic Information, Sales Area and Its Competitors
  • Table 148. Infectious Diseases: by Type(USD Million)
  • Table 149. Infectious Diseases Reagents and Kits , by Region USD Million (2025-2030)
  • Table 150. Infectious Diseases Instrument , by Region USD Million (2025-2030)
  • Table 151. Infectious Diseases Software , by Region USD Million (2025-2030)
  • Table 152. Infectious Diseases: by Infectious Disease Type(USD Million)
  • Table 153. Infectious Diseases Viral Infections , by Region USD Million (2025-2030)
  • Table 154. Infectious Diseases Bacterial Infections , by Region USD Million (2025-2030)
  • Table 155. Infectious Diseases Fungal Infections , by Region USD Million (2025-2030)
  • Table 156. Infectious Diseases Parasitic Infections , by Region USD Million (2025-2030)
  • Table 157. Infectious Diseases Others , by Region USD Million (2025-2030)
  • Table 158. Infectious Diseases: by Technology(USD Million)
  • Table 159. Infectious Diseases Immunodiagnostics , by Region USD Million (2025-2030)
  • Table 160. Infectious Diseases Polymerase Chain Reaction (PCR) , by Region USD Million (2025-2030)
  • Table 161. Infectious Diseases Isothermal Nucleic Acid Amplification Technology (INAAT) , by Region USD Million (2025-2030)
  • Table 162. Infectious Diseases DNA Sequencing and Next-Generation Sequencing (NGS) , by Region USD Million (2025-2030)
  • Table 163. Infectious Diseases DNA Microarray , by Region USD Million (2025-2030)
  • Table 164. Infectious Diseases Others , by Region USD Million (2025-2030)
  • Table 165. Infectious Diseases: by End User(USD Million)
  • Table 166. Infectious Diseases Hospitals and Clinics , by Region USD Million (2025-2030)
  • Table 167. Infectious Diseases Laboratories , by Region USD Million (2025-2030)
  • Table 168. Infectious Diseases Academic and Research Institutes , by Region USD Million (2025-2030)
  • Table 169. Infectious Diseases Others , by Region USD Million (2025-2030)
  • Table 170. South America Infectious Diseases, by Country USD Million (2025-2030)
  • Table 171. South America Infectious Diseases, by Type USD Million (2025-2030)
  • Table 172. South America Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 173. South America Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 174. South America Infectious Diseases, by End User USD Million (2025-2030)
  • Table 175. Brazil Infectious Diseases, by Type USD Million (2025-2030)
  • Table 176. Brazil Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 177. Brazil Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 178. Brazil Infectious Diseases, by End User USD Million (2025-2030)
  • Table 179. Argentina Infectious Diseases, by Type USD Million (2025-2030)
  • Table 180. Argentina Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 181. Argentina Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 182. Argentina Infectious Diseases, by End User USD Million (2025-2030)
  • Table 183. Rest of South America Infectious Diseases, by Type USD Million (2025-2030)
  • Table 184. Rest of South America Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 185. Rest of South America Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 186. Rest of South America Infectious Diseases, by End User USD Million (2025-2030)
  • Table 187. Asia Pacific Infectious Diseases, by Country USD Million (2025-2030)
  • Table 188. Asia Pacific Infectious Diseases, by Type USD Million (2025-2030)
  • Table 189. Asia Pacific Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 190. Asia Pacific Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 191. Asia Pacific Infectious Diseases, by End User USD Million (2025-2030)
  • Table 192. China Infectious Diseases, by Type USD Million (2025-2030)
  • Table 193. China Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 194. China Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 195. China Infectious Diseases, by End User USD Million (2025-2030)
  • Table 196. Japan Infectious Diseases, by Type USD Million (2025-2030)
  • Table 197. Japan Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 198. Japan Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 199. Japan Infectious Diseases, by End User USD Million (2025-2030)
  • Table 200. India Infectious Diseases, by Type USD Million (2025-2030)
  • Table 201. India Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 202. India Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 203. India Infectious Diseases, by End User USD Million (2025-2030)
  • Table 204. South Korea Infectious Diseases, by Type USD Million (2025-2030)
  • Table 205. South Korea Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 206. South Korea Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 207. South Korea Infectious Diseases, by End User USD Million (2025-2030)
  • Table 208. Taiwan Infectious Diseases, by Type USD Million (2025-2030)
  • Table 209. Taiwan Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 210. Taiwan Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 211. Taiwan Infectious Diseases, by End User USD Million (2025-2030)
  • Table 212. Australia Infectious Diseases, by Type USD Million (2025-2030)
  • Table 213. Australia Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 214. Australia Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 215. Australia Infectious Diseases, by End User USD Million (2025-2030)
  • Table 216. Rest of Asia-Pacific Infectious Diseases, by Type USD Million (2025-2030)
  • Table 217. Rest of Asia-Pacific Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 218. Rest of Asia-Pacific Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 219. Rest of Asia-Pacific Infectious Diseases, by End User USD Million (2025-2030)
  • Table 220. Europe Infectious Diseases, by Country USD Million (2025-2030)
  • Table 221. Europe Infectious Diseases, by Type USD Million (2025-2030)
  • Table 222. Europe Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 223. Europe Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 224. Europe Infectious Diseases, by End User USD Million (2025-2030)
  • Table 225. Germany Infectious Diseases, by Type USD Million (2025-2030)
  • Table 226. Germany Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 227. Germany Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 228. Germany Infectious Diseases, by End User USD Million (2025-2030)
  • Table 229. France Infectious Diseases, by Type USD Million (2025-2030)
  • Table 230. France Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 231. France Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 232. France Infectious Diseases, by End User USD Million (2025-2030)
  • Table 233. Italy Infectious Diseases, by Type USD Million (2025-2030)
  • Table 234. Italy Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 235. Italy Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 236. Italy Infectious Diseases, by End User USD Million (2025-2030)
  • Table 237. United Kingdom Infectious Diseases, by Type USD Million (2025-2030)
  • Table 238. United Kingdom Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 239. United Kingdom Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 240. United Kingdom Infectious Diseases, by End User USD Million (2025-2030)
  • Table 241. Netherlands Infectious Diseases, by Type USD Million (2025-2030)
  • Table 242. Netherlands Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 243. Netherlands Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 244. Netherlands Infectious Diseases, by End User USD Million (2025-2030)
  • Table 245. Rest of Europe Infectious Diseases, by Type USD Million (2025-2030)
  • Table 246. Rest of Europe Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 247. Rest of Europe Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 248. Rest of Europe Infectious Diseases, by End User USD Million (2025-2030)
  • Table 249. MEA Infectious Diseases, by Country USD Million (2025-2030)
  • Table 250. MEA Infectious Diseases, by Type USD Million (2025-2030)
  • Table 251. MEA Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 252. MEA Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 253. MEA Infectious Diseases, by End User USD Million (2025-2030)
  • Table 254. Middle East Infectious Diseases, by Type USD Million (2025-2030)
  • Table 255. Middle East Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 256. Middle East Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 257. Middle East Infectious Diseases, by End User USD Million (2025-2030)
  • Table 258. Africa Infectious Diseases, by Type USD Million (2025-2030)
  • Table 259. Africa Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 260. Africa Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 261. Africa Infectious Diseases, by End User USD Million (2025-2030)
  • Table 262. North America Infectious Diseases, by Country USD Million (2025-2030)
  • Table 263. North America Infectious Diseases, by Type USD Million (2025-2030)
  • Table 264. North America Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 265. North America Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 266. North America Infectious Diseases, by End User USD Million (2025-2030)
  • Table 267. United States Infectious Diseases, by Type USD Million (2025-2030)
  • Table 268. United States Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 269. United States Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 270. United States Infectious Diseases, by End User USD Million (2025-2030)
  • Table 271. Canada Infectious Diseases, by Type USD Million (2025-2030)
  • Table 272. Canada Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 273. Canada Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 274. Canada Infectious Diseases, by End User USD Million (2025-2030)
  • Table 275. Mexico Infectious Diseases, by Type USD Million (2025-2030)
  • Table 276. Mexico Infectious Diseases, by Infectious Disease Type USD Million (2025-2030)
  • Table 277. Mexico Infectious Diseases, by Technology USD Million (2025-2030)
  • Table 278. Mexico Infectious Diseases, by End User USD Million (2025-2030)
  • Table 279. Research Programs/Design for This Report
  • Table 280. Key Data Information from Secondary Sources
  • Table 281. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Infectious Diseases: by Type USD Million (2018-2023)
  • Figure 5. Global Infectious Diseases: by Infectious Disease Type USD Million (2018-2023)
  • Figure 6. Global Infectious Diseases: by Technology USD Million (2018-2023)
  • Figure 7. Global Infectious Diseases: by End User USD Million (2018-2023)
  • Figure 8. South America Infectious Diseases Share (%), by Country
  • Figure 9. Asia Pacific Infectious Diseases Share (%), by Country
  • Figure 10. Europe Infectious Diseases Share (%), by Country
  • Figure 11. MEA Infectious Diseases Share (%), by Country
  • Figure 12. North America Infectious Diseases Share (%), by Country
  • Figure 13. Global Infectious Diseases share by Players 2023 (%)
  • Figure 14. Global Infectious Diseases share by Players (Top 3) 2023(%)
  • Figure 15. Global Infectious Diseases share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Quagen Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 18. Quagen Pharma (United States) Revenue: by Geography 2023
  • Figure 19. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 21. BioMérieux (France) Revenue, Net Income and Gross profit
  • Figure 22. BioMérieux (France) Revenue: by Geography 2023
  • Figure 23. Bio-Rad Laboratories Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Bio-Rad Laboratories Inc. (United States) Revenue: by Geography 2023
  • Figure 25. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 26. Danaher Corporation (United States) Revenue: by Geography 2023
  • Figure 27. DiaSorin S.p.A. (Italy) Revenue, Net Income and Gross profit
  • Figure 28. DiaSorin S.p.A. (Italy) Revenue: by Geography 2023
  • Figure 29. BD (United States) Revenue, Net Income and Gross profit
  • Figure 30. BD (United States) Revenue: by Geography 2023
  • Figure 31. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 32. Abbott (United States) Revenue: by Geography 2023
  • Figure 33. Siemens (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Siemens (Germany) Revenue: by Geography 2023
  • Figure 35. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Johnson and Johnson Private Limited (United States) Revenue, Net Income and Gross profit
  • Figure 38. Johnson and Johnson Private Limited (United States) Revenue: by Geography 2023
  • Figure 39. Cepheid (United States) Revenue, Net Income and Gross profit
  • Figure 40. Cepheid (United States) Revenue: by Geography 2023
  • Figure 41. OraSure Technologies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. OraSure Technologies, Inc. (United States) Revenue: by Geography 2023
  • Figure 43. Meridian Bioscience Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Meridian Bioscience Inc. (United States) Revenue: by Geography 2023
  • Figure 45. Quidel Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 46. Quidel Corporation (United States) Revenue: by Geography 2023
  • Figure 47. Grifols (Spain) Revenue, Net Income and Gross profit
  • Figure 48. Grifols (Spain) Revenue: by Geography 2023
  • Figure 49. Global Infectious Diseases: by Type USD Million (2025-2030)
  • Figure 50. Global Infectious Diseases: by Infectious Disease Type USD Million (2025-2030)
  • Figure 51. Global Infectious Diseases: by Technology USD Million (2025-2030)
  • Figure 52. Global Infectious Diseases: by End User USD Million (2025-2030)
  • Figure 53. South America Infectious Diseases Share (%), by Country
  • Figure 54. Asia Pacific Infectious Diseases Share (%), by Country
  • Figure 55. Europe Infectious Diseases Share (%), by Country
  • Figure 56. MEA Infectious Diseases Share (%), by Country
  • Figure 57. North America Infectious Diseases Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Quagen Pharma (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • bioMérieux (France)
  • Bio-Rad Laboratories Inc. (United States)
  • Danaher Corporation (United States)
  • DiaSorin S.p.A. (Italy)
  • BD (United States)
  • Abbott (United States)
  • Siemens (Germany)
  • Thermo Fisher Scientific Inc. (United States)
  • Johnson and Johnson Private Limited (United States)
  • Cepheid (United States)
  • OraSure Technologies, Inc. (United States)
  • Meridian Bioscience Inc. (United States)
  • Quidel Corporation (United States)
  • Grifols (Spain)
Select User Access Type

Key Highlights of Report


Feb 2024 227 Pages 67 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Infectious Diseases Quantitative research analysis
Global Infectious Diseases Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Infectious Diseases market are Quagen Pharma (United States), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Bio-Rad Laboratories Inc. (United States), Danaher Corporation (United States), DiaSorin S.p.A. (Italy), BD (United States), Abbott (United States), Siemens (Germany), Thermo Fisher Scientific Inc. (United States), Johnson and Johnson Private Limited (United States), Cepheid (United States), OraSure Technologies, Inc. (United States), Meridian Bioscience Inc. (United States), Quidel Corporation (United States) and Grifols (Spain), to name a few.
is dominating the Infectious Diseases Market.
"Stringent regulatory policies" is seen as one of the major challenges by many Industry Players of Infectious Diseases Market
The Infectious Diseases market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Infectious Diseases market is expected to see a steady growth rate during projected year 2023 to 2030.

Know More About Global Infectious Diseases Report?

Have a Query? Click Here

Other Related Reports

Renal Denervation Treatment Comprehensive Study by Application (Hospitals, Ambulatory Surgical Centers, Others), Technology (Ultrasound, Radiofrequency, Ultrasound, Micro-infusion), Diseases (Hyperte...
$ 3350
Chronic Fatigue Syndrome Treatment Comprehensive Study by Application (Hospitals, Clinics, Research Institutes), Distribution Channel (Hospital Pharmacies, Retails Pharmacies, Online Pharmacies), Mod...
$ 3750
Childhood Vaccines Comprehensive Study by Type (Monovalent Vaccines, Multivalent Vaccines), Route of Administration (Intramuscular and Subcutaneous Administration, Oral Administration, Others), Techn...
$ 3750
Bone Marrow Transplantation Comprehensive Study by Type (Allogeneic Bone Marrow Transplant, Autologous Bone Marrow Transplant), Indication (Leukemia, Lymphoma, Myeloma, Myelodysplasia, Myeloprolifera...
$ 3650
Anti-aging Services Comprehensive Study by Type (Face, Body), Form (Cream, Serum, Gel), Ingredient (Vitamin E, Vitamin C, Retinol, Aloe, Shea Butter, Alpha Hydroxy), Container (Jar, Bottle, Tube, Pu...
$ 3500
Paget's Disease Treatment Comprehensive Study by Route of Administration (Oral, Intravenous, Topical), Treatment (Actonel, Reclast, Zoledronic Acid, Fosamax, Miacalcin, Aredia, Calcitonin, Zometa, Ot...
$ 3750